Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products

Abstract The number of mesenchymal stromal/stem cell (MSC) therapeutics and types of clinical applications have greatly diversified during the past decade, including rapid growth of poorly regulated “Stem Cell Clinics” offering diverse “Unproven Stem Cell Interventions.” This product diversification...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Stem cells translational medicine Ročník 11; číslo 1; s. 2 - 13
Hlavní autoři:	Moll, Guido, Ankrum, James A, Olson, Scott D, Nolta, Jan A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	US Oxford University Press 03.03.2022
Témata:	Blood Coagulation Case reports Clinical trials Humans Mesenchymal Stem Cell Transplantation - adverse effects Mesenchymal Stem Cells - metabolism Patient safety Stem cells Therapeutic applications Thromboembolism Thromboplastin - metabolism Tissue factor mesenchymal stromal/stem cells (MSCs) product diversification hemocompatibility thromboembolism safety and efficacy coagulopathy cellular therapy tissue source coagulation tissue factor/CD142/Factor III/F3
ISSN:	2157-6564, 2157-6580, 2157-6580
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!